The company shifted strategy around eight years ago to meet the needs of large cloud providers, wrote UBS lead analyst David ...
41 分钟on MSN
Karyopharm signals $1B annual U.S. peak revenue opportunity for selinexor in myelofibrosis ...
Q3 2025 Management View Richard Paulson, President and CEO, highlighted a "very productive quarter for Karyopharm, one defined by meaningful clinical progress and strengthened financial flexibility ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果